pembrolizumab
merck
['nsclc', 'sclc', 'pembro']
with longer follow up, os favors pembrolizumab arm with mos 17.2 vs 11.6m (os hr 0.71) in squamous nsclc. 5y os rate 18.4% vs 9.7%. pfs benefit (hr 0.62) and higher rr across pdl1 strata. #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him